Cambridge biotech Alchemab Therapeutics has extended its Series A round with a £25 million ($34 million) investment from the British Business Bank, which the company says is the state-owned lender’s largest backing of a life sciences company to date. The money will help the clinical-stage firm build its drug pipeline and expand a proprietary antibody […]<br /> This story continues at The Next Web [...]
On a recent work trip, I had plenty of things to worry about — but being able to recharge my two smartphones, laptop and iPad were not among my concerns. In my carry-on luggage, I had two medium-cap [...]
The journey from a laboratory hypothesis to a pharmacy shelf is one of the most grueling marathons in modern industry, typically spanning 10 to 15 years and billions of dollars in investment. Progress [...]
Alphabet's life sciences business Verily is restructuring and raising money as a new corporate entity. Verily announced that with its $300 million investment round, it will change from an LLC to [...]
Fleek, a London startup building the software plumbing behind the global secondhand clothing trade, has raised $25m in Series B funding to scale the AI it uses to sort, grade and price used garments. [...]
OpenAI has introduced GPT-Rosalind, a reasoning model tailored for the life sciences. It's designed to help researchers move faster from hypothesis to experiment. Access is tightly controlled for [...]
OpenAI is offering its life sciences model GPT-Rosalind for free through the new Rosalind Biodefense program, aimed at pandemic preparedness and biodefense. Early partners include Lawrence Livermore N [...]